Bone Marrow TransplantationTransplantation, HomologousHematopoietic Stem Cell TransplantationStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousBone MarrowHematologic NeoplasmsTransplantation ChimeraBone Marrow CellsPeripheral Blood Stem Cell TransplantationTissue DonorsBusulfanWhole-Body IrradiationTreatment OutcomeStem CellsGraft SurvivalLeukemiaRecurrenceRemission InductionGraft vs Leukemia EffectHistocompatibility TestingLiver TransplantationGraft vs Tumor EffectHematopoietic Stem CellsMyeloablative AgonistsAnemia, AplasticLeukemia, Myeloid, AcuteImmunosuppressive AgentsCombined Modality TherapyHistocompatibilityLeukemia, Myelogenous, Chronic, BCR-ABL PositiveVidarabineLymphocyte TransfusionCyclophosphamideRetrospective StudiesLymphocyte DepletionPrecursor Cell Lymphoblastic Leukemia-LymphomaMultiple MyelomaSurvival AnalysisCytomegalovirus InfectionsMyelodysplastic SyndromesKidney TransplantationTime FactorsHepatic Veno-Occlusive DiseaseCord Blood Stem Cell TransplantationDisease-Free SurvivalSurvival RateBone and BonesSalvage TherapyAntilymphocyte SerumMinor Histocompatibility AntigensSiblingsMelphalanAcute DiseaseTransplantation, IsogeneicT-LymphocytesAntineoplastic Combined Chemotherapy ProtocolsNeoplasm, ResidualTransplantation ImmunologyHLA AntigensChimerismImmunosuppressionLeukemia, MyeloidGraft RejectionBone Marrow PurgingHematologic DiseasesFollow-Up StudiesVirus ActivationLymphoma, Non-HodgkinHematopoietic Stem Cell MobilizationCell TransplantationMesenchymal Stem Cell TransplantationHeart TransplantationHematopoiesisCytarabineLeukocyte TransfusionMice, Inbred C57BLPrognosisAntigens, CD34CytomegalovirusCyclosporineNuclear FamilyPrimary MyelofibrosisGranulocyte Colony-Stimulating FactorHodgkin DiseaseLung TransplantationCell DifferentiationBone Marrow DiseasesActuarial AnalysisImmunocompromised HostLymphoproliferative DisordersFatal OutcomeInfectionLeukemia, Myeloid, Accelerated PhaseRadiation ChimeraFlow CytometryEtoposideAntineoplastic Agents